We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.51 | 2.06M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/2/2021 19:50 | The exploratory objectives plus lots of other information are detailed here in case anybody was wondering where MM got the info above: | on target | |
17/2/2021 18:41 | Prof Chalmers lab have been involved in the following study published today, and their research and new observations on neutrophils, implicated in multiple inflammatory diseases, could be of significance to Prof Chalmers upcoming interim data analysis on SFX-01's efficacy, given that their study is also part of the Covid/Ards trial. Gla :-) James D Chalmers Retweeted The Lancet Respiratory Medicine @LancetRespirMed · 1h NEW Research—Neutr ProfJDChalmers · 1h An international collaborative study involving patients from UK, Spain, Italy and Australia and an incredible collaborative team Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an... thelancet.com Log in ARTICLES|ONLINE FIRST Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study Summary Background Bronchiectasis is predominantly a neutrophilic inflammatory disease. There are no established therapies that directly target neutrophilic inflammation because little is understood of the underlying mechanisms leading to severe disease. Neutrophil extracellular trap (NET) formation is a method of host defence that has been implicated in multiple inflammatory diseases. We aimed to investigate the role of NETs in disease severity and treatment response in bronchiectasis. ........ Exploratory objectives of SFX-01's Covid/Ards trial. Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells Neutrophil functional studies in isolated cells Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood | moneymunch | |
17/2/2021 17:23 | It will blow lateral flow out of the water ..... anything diagnostic I'm on it ... Sheffield university involved. | amaretto1 | |
17/2/2021 17:21 | U all need to look at BRH Braveheart .....If there test results due early next week are successful ....Imo it's what the Goverment are going to use ... and announce this next week .Very accurate 5 min test !!Problem... very difficult to buy shares in them :-( | amaretto1 | |
17/2/2021 17:04 | They'll have to wait for the open offer deadline before confirming any excess shares. | on target | |
17/2/2021 17:03 | On to the other 85k | amaretto1 | |
17/2/2021 17:02 | Yes ... I've added another 100k !!May get them may not | amaretto1 | |
17/2/2021 15:21 | Is the entitlement usually only 1:11 though brasso? | on target | |
17/2/2021 14:30 | You always get extra shares in these offerings. | brasso3 | |
17/2/2021 14:12 | Yep, but i've got a feeling demand will outstrip supply and so might be a struggle getting extra. Gl ;-) | moneymunch | |
17/2/2021 13:47 | Got my allocation rights in HL , is anyone applying for more? | markth126 | |
17/2/2021 13:45 | Yep, but presumably the majority of transactions to take them back over 3% were in by the 10th??? | moneymunch | |
17/2/2021 13:37 | 12/2 is too late for the entitlement, had to be in by the 10th. | on target | |
17/2/2021 12:58 | Hi On Target, presumably pi's who use Intratrader platform, who wanted back in to qualify for the 8p entitlement...we probably won't get disclosure of those that have taken a share of the £10m until after 4th March, admission day. Gl ;-) | moneymunch | |
17/2/2021 12:37 | Ha Rb, sorry i’d missed the Intertrader RNS! | bumpa33 | |
17/2/2021 12:30 | Doesn't look related to the placing because it hasn't happened yet, and the RNS says they increased on 12/2. | on target | |
17/2/2021 12:28 | I think so bocker, it just wouldn't make any sense in these unprecedenteded times to waste valuable time and resources on a drug that doesn't work, and so no surprise and the obvious reason why Prof Chalmers will assess SFX 01's efficacy from the interim data....which we now await with great excitement. :-) | moneymunch | |
17/2/2021 12:16 | The Inter Trader holdings position :) | riggerbeautz | |
17/2/2021 12:11 | You’ve lost me Rb...?! | bumpa33 | |
17/2/2021 12:08 | Thought you had been adding to your Gibraltar holding for a minute lol | riggerbeautz | |
17/2/2021 12:05 | Rb - yep, time to sit on hands from here on in. | bumpa33 | |
17/2/2021 11:50 | Post 75 MM - yes its just common sense isn't it! | bocker01 | |
17/2/2021 11:36 | A long term hold with undoubted Transformational upside potential, near , mid and long term. Gla :-) | moneymunch |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions